Our findings collectively open new avenues for research into the proteome alterations in amyloid diseases and elucidation of several key proteins that have the potential to be leveraged as biomarkers for V30M ATTRv-PN, including TTR itself, CP, APOE, and the complement pathway proteins such as C3. This evidence concerns the gene C3 and amyloidosis.